Clin Osteol 2022; 27(4): 131-134

Does hormone replacement therapy have a place in the prevention of osteoporosis?Review articles

Fait Tomáš1,2
1 Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha
2 Katedra zdravotních studií VŠP Jihlava

Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture. In case of the early start of it benefits overweight risks. We do individual tailoring of therapy by doses, components, application way and total period of use.

Keywords: genitourinary syndrome of menopause; menopause; osteoporosis; hormone therapy; hot flushes

Received: August 17, 2022; Accepted: September 20, 2022; Published: December 11, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fait T. Does hormone replacement therapy have a place in the prevention of osteoporosis? Clinical Osteology. 2022;27(4):131-134.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. 1. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2 018; 25(11): 1362-1387. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000001241>. Go to original source...
    2. 2. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022; 29(7): 767-794. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000002028>. Go to original source...
    3. 3. Thurston R, Chang Y, Barinas-Mitchel E et al. Physiologically assessed hot flashes and endothelial function among midlife women. Menopause 2017; 24(8): 886-893. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000000857>.
    4. 4. Biglia N, Cagnacci A, Gambacciani M et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric 2017; 20(4): 306-312. Dostupné z DOI: <http://dx.doi.org/10.1080/13697137.2017.1315089>.
    5. 5. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am 2015; 44(3): 497-515. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ecl.2015.05.001>.
    6. 6. Herber-Gast B, Brown WJ, Mishra GD. Hot flushes and night sweats are associated with coronary heart disease risk in midlife: a longitudinal study. BJOG 2015; 122(11): 1560-1567. Dostupné z DOI: <http://dx.doi.org/10.1111/1471-0528.13163>.
    7. 7. Thurston RC, Aizenstein HJ, Derby CA et al. Menopausal hot flashes and white matter hyperintensities. Menopause 2016; 23(1): 27-32. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000000481>
    8. 8. Fait T, Donát J, Jeníček J et al. Doporučení pro hormonální substituční terapii v postmenopauze. Čes Gynek 2010; 75(2): 109-110.
    9. 9. Notelovitz M, Lenihan JP, McDermont M et al. Initial 17beta-estradioldose for treating vasomotor symptoms. Obstet Gynekol 2000; 95(5): 726-731. Dostupné z DOI: <http://dx.doi.org/10.1016/s0029-7844(99)00643-2>.
    10. 10. Panay N, Ylikorkala O, Archer DF et al. Ultra-low-dose estradiol and norethisteron acetate: effective menopausal symptom relief. Climacteric 2007; 10(2): 120-131. Dostupné z DOI: <http://dx.doi.org/10.1080/13697130701298107>.
    11. 11. Stevenson JC, Durand G, Kahler E et al. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010; 6 7(3): 2 27-232. D ostupné z DOI: < http://dx.doi.org/10.1016/j.maturitas.2010.07.002>
    12. 12. Gambacciani M, Cappagli B, Ciaponi M et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008; 59(1): 2-6. Dostupné z DOI: <http://dx.doi.org/10.1016/j.maturitas.2007.10.007>.
    13. 13. Lundström F, Bydgeson M, Svane G et al. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 2007; 10(3): 249-225. Dostupné z DOI: <http://dx.doi.org/10.1080/13697130701385805>.
    14. 14. Sturdee DW, Archer DF, Rakov V et al. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric 2008; 11(1): 63-73. Dostupné z DOI: <http://dx.doi.org/10.1080/13697130701852390>.
    15. 15. Bergeron C, Nogales FF, Rechberger T et al. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate. Maturitas 2010; 66(2): 201-205. Dostupné z DOI: <http://dx.doi.org/10.1016/j.maturitas.2010.03.007>.
    16. 16. Koire A, Joffe H, Buckley R. Menopausal Hormone Therapy and the Mind: The Role of Hormone Replacement in the Prevention and Treatment of Cognitive Decline, Dementia, and Cognitive Dysfunction of Depression. Harv Rev Psychiatry 2022; 30(4): 215-22. Dostupné z DOI: <http://dx.doi.org/10.1097/HRP.0000000000000339>.
    17. 17. Kim J, Chang JH, Jeong MJ et al. A systematic review and metaanalysisof effects of menopause hormone therapy on cardiovascular diseases. Sci Rep 2020; 10(1): 20631. Dostupné z DOI: <http://dx.doi.org/10.1038/s41598-020-77534-9>.
    18. 18. Tan DA, Dayu AR. Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. Climacteric 2022; 25(4): 362-368. Dostupné z DOI: <http://dx.doi.org/10.1080/13697137.2022.2035711>.
    19. 19. Cauley JA, Robbins J, Chen Z et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women´s Health Initiative randomized trial. JAMA 2003; 290(13): 1729-1738. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.290.13.1729>.
    20. 20. Robbins JA, Argaki A, Crandall CJ et al. WHI trials: interaction of calcium and vitamin D with hormone therapy. Menopause 2014; 2 1(2): 1 16-123. D ostupné z DOI: < http://dx.doi.org/10.1097/GME.0b013e3182963901>.
    21. 21. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fracture: a meta-analysis of randomized trials. JAMA 2001; 285(22): 2891-2897. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.285.22.2891>.
    22. 22. Zhu L, Jiang X, Sun Y et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause 2016; 23(4): 461-470. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000000519>.
    23. 23. Jiang X, Kagan R. Hormone therapy for osteoporosis management. Climacteric 2022; 25(1): 50-55. Dostupné z DOI: <http://dx.doi.org/10.1080/13697137.2021.1957818>.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.